Screener
Janux Therapeutics JANX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's retained earnings?
- Janux Therapeutics (JANX) reported retained earnings of -$397.72M in Q2 2026.
- How has Janux Therapeutics's retained earnings changed year-over-year?
- Janux Therapeutics's retained earnings decreased by 34.8% year-over-year, from -$295.12M to -$397.72M.
- What is the long-term trend for Janux Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Janux Therapeutics's retained earnings has grown at a 88.6% compound annual growth rate (CAGR), from -$14.74M to -$351.38M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Janux Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude